Safety and efficacy of pd-1/pd-l1 inhibitors in cancer patients with preexisting autoantibodies

HIGHLIGHTS

• who: Hui Tang from the Australia Australian National University, Australia have published the paper: Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies, in the Journal: (JOURNAL)
• what: The present retrospective cohort study aimed to evaluate the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients with preexisting autoantibodies. In the present study, Kaplan-Meier curves and log-rank tests showed patients with ANA or any preexisting antibody had better PFS, while LASSO and Cox regression analysis demonstrated that only ANA was an independent indicator of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.